Cited by 113Seaweed-derived Bioactive CompoundsColorectal Cancer Treatments and StudiesCancer survivorship and care

Fucoidan reduces the toxicities of chemotherapy for patients with unresectable advanced or recurrent colorectal cancer

Open access
IKEGUCHI, MASAHIDE, YAMAMOTO, MANABU, ARAI, YOSUKE, MAETA, YOSHIHIKO, ASHIDA, KEIGO, KATANO, KUNIYUKI, MIKI, YASUNARI, KIMURA, TAKAYUKI·2011·Oncology Letters

Abstract

Combination chemotherapy with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) or irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) has become a standard regimen for advanced or recurrent colorectal cancer. Numerous studies have reported that long-term use of FOLFOX or FOLFIRI leads to better survival for these patients. Thus, control of the toxicity of these drugs may be crucial to prolonging survival. Fucoidan is one of the major sulfated polysaccharides of brown seaweeds and exhibits a wide range of biological activities. In the present study, we analyzed the effect of fucoidan on suppressing the toxicity of anti-cancer drugs. A total of 20 patients with unresectable advanced or recurrent colorectal cancer scheduled to undergo treatment with FOLFOX or FOLFIRI were randomly allocated into a fucoidan treatment group (n=10) and a control group without fucoidan treatment (n=10). Results showed that fucoidan regulated the occurrence of fatigue during chemotherapy. Chemotherapy with fucoidan was continued for a longer period than chemotherapy without fucoidan. Additionally, the survival of patients with fucoidan treatment was longer than that of patients without fucoidan, although the difference was not significant. Thus, fucoidan may enable the continuous administration of chemotherapeutic drugs for patients with unresectable advanced or recurrent colorectal cancer, and as a result, the prognosis of such patients is prolonged.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/ol.2011.254

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
IKEGUCHI, M., YAMAMOTO, M., ARAI, Y., MAETA, Y., ASHIDA, K., KATANO, K., MIKI, Y., & KIMURA, T.
Affiliations
Tottori University (JP)
Venue
Oncology Letters
Published
2011-01-21
Volume
2
Issue
2
Pages
319-322
ISSN
  • 1792-1074 (ISSN-L)
  • 1792-1082
OpenAlex
W2046122149
Cited by
113
References
20
Citations by year
2026: 6 · 2025: 6 · 2024: 5 · 2023: 11 · 2022: 11 · 2021: 12 · 2020: 13 · 2019: 15 · 2018: 4 · 2017: 6 · 2016: 7 · 2015: 6 · 2014: 6 · 2013: 4
FWCI
5.34
Type
journal article
Language
en
Open access
Locations
  • Oncology Letters (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Agricultural and Biological Sciences › Aquatic Science › Seaweed-derived Bioactive Compounds
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
Keywords
fucoidan, colorectal cancer, chemotherapy toxicity, FOLFOX, FOLFIRI, oxaliplatin, irinotecan, fatigue, survival, sulfated polysaccharides, brown algae

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review